397 related articles for article (PubMed ID: 37390836)
1. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.
Stephenson KE; Tan CS; Walsh SR; Hale A; Ansel JL; Kanjilal DG; Jaegle K; Peter L; Borducchi EN; Nkolola JP; Makoni T; Fogel R; Bradshaw C; Tyler A; Moseley E; Chandrashekar A; Yanosick KE; Seaman MS; Eckels KH; De La Barrera RA; Thompson J; Dawson P; Thomas SJ; Michael NL; Modjarrad K; Barouch DH
Lancet Infect Dis; 2020 Sep; 20(9):1061-1070. PubMed ID: 32618279
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial.
Han HH; Diaz C; Acosta CJ; Liu M; Borkowski A
Lancet Infect Dis; 2021 Sep; 21(9):1282-1292. PubMed ID: 34019802
[TBL] [Abstract][Full Text] [Related]
4. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine.
Li Y; Merbah M; Wollen-Roberts S; Beckman B; Mdluli T; Curtis DJ; Currier JR; Mendez-Rivera L; Dussupt V; Krebs SJ; De La Barrera R; Michael NL; Paquin-Proulx D; Eller MA; Koren MA; Modjarrad K; Rolland M
EBioMedicine; 2023 Nov; 97():104815. PubMed ID: 37793212
[TBL] [Abstract][Full Text] [Related]
5. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
Modjarrad K; Lin L; George SL; Stephenson KE; Eckels KH; De La Barrera RA; Jarman RG; Sondergaard E; Tennant J; Ansel JL; Mills K; Koren M; Robb ML; Barrett J; Thompson J; Kosel AE; Dawson P; Hale A; Tan CS; Walsh SR; Meyer KE; Brien J; Crowell TA; Blazevic A; Mosby K; Larocca RA; Abbink P; Boyd M; Bricault CA; Seaman MS; Basil A; Walsh M; Tonwe V; Hoft DF; Thomas SJ; Barouch DH; Michael NL
Lancet; 2018 Feb; 391(10120):563-571. PubMed ID: 29217375
[TBL] [Abstract][Full Text] [Related]
6. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.
Essink B; Chu L; Seger W; Barranco E; Le Cam N; Bennett H; Faughnan V; Pajon R; Paila YD; Bollman B; Wang S; Dooley J; Kalidindi S; Leav B
Lancet Infect Dis; 2023 May; 23(5):621-633. PubMed ID: 36682364
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
8. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
9. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
11. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
Kallas EG; Precioso AR; Palacios R; Thomé B; Braga PE; Vanni T; Campos LMA; Ferrari L; Mondini G; da Graça Salomão M; da Silva A; Espinola HM; do Prado Santos J; Santos CLS; Timenetsky MDCST; Miraglia JL; Gallina NMF; Weiskopf D; Sette A; Goulart R; Salles RT; Maestri A; Sallum AME; Farhat SCL; Sakita NK; Ferreira JCOA; Silveira CGT; Costa PR; Raw I; Whitehead SS; Durbin AP; Kalil J
Lancet Infect Dis; 2020 Jul; 20(7):839-850. PubMed ID: 32220283
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
Gaudinski MR; Houser KV; Morabito KM; Hu Z; Yamshchikov G; Rothwell RS; Berkowitz N; Mendoza F; Saunders JG; Novik L; Hendel CS; Holman LA; Gordon IJ; Cox JH; Edupuganti S; McArthur MA; Rouphael NG; Lyke KE; Cummings GE; Sitar S; Bailer RT; Foreman BM; Burgomaster K; Pelc RS; Gordon DN; DeMaso CR; Dowd KA; Laurencot C; Schwartz RM; Mascola JR; Graham BS; Pierson TC; Ledgerwood JE; Chen GL; ;
Lancet; 2018 Feb; 391(10120):552-562. PubMed ID: 29217376
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
Juan-Giner A; Kimathi D; Grantz KH; Hamaluba M; Kazooba P; Njuguna P; Fall G; Dia M; Bob NS; Monath TP; Barrett AD; Hombach J; Mulogo EM; Ampeire I; Karanja HK; Nyehangane D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
Lancet; 2021 Jan; 397(10269):119-127. PubMed ID: 33422245
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W
Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM
Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
